Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alkermes Plc (ALKS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,979,901
  • Shares Outstanding, K 155,040
  • Annual Sales, $ 903,370 K
  • Annual Income, $ -157,950 K
  • 36-Month Beta 1.80
  • Price/Sales 7.74
  • Price/Cash Flow 163.66
  • Price/Book 6.05

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.54 +13.86%
on 06/28/18
51.70 -12.92%
on 06/19/18
-5.75 (-11.33%)
since 06/18/18
3-Month
39.54 +13.86%
on 06/28/18
51.70 -12.92%
on 06/19/18
-1.83 (-3.91%)
since 04/18/18
52-Week
39.54 +13.86%
on 06/28/18
71.22 -36.79%
on 02/16/18
-12.99 (-22.39%)
since 07/18/17

Most Recent Stories

More News
Alkermes' Aristada Initio Approved by FDA for Schizophrenia

FDA approves Alkermes' (ALKS) Aristada Initio (aripiprazole lauroxil) for the treatment of schizophrenia in adults.

AGLE : 9.36 (+3.54%)
ILMN : 307.28 (+0.59%)
ANIP : 70.86 (+1.13%)
ALKS : 45.02 (-0.22%)
Company News For Jul 3, 2018

Companies in the news are: CLB, ALKS, ACXM and URI

CLB : 114.86 (-0.03%)
ACXM : 43.60 (-0.95%)
URI : 154.91 (+1.77%)
ALKS : 45.02 (-0.22%)
FDA Approves ARISTADA INITIO(TM) for the Initiation of ARISTADA® for Schizophrenia

Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA INITIO(TM) (aripiprazole lauroxil) for the initiation of ARISTADA® (aripiprazole lauroxil),...

ALKS : 45.02 (-0.22%)
Alkermes Plc Set to Possibly Rebound After Yesterday's Selloff of 12.34%

Alkermes Plc (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $44.95 to a high of $48.80. Yesterday, the shares fell 12.3%, which took the trading range below the 3-day low of $48.89...

ALKS : 45.02 (-0.22%)
Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks

Stock Research Monitor: AIMT, PETX, and ABIO

AIMT : 29.06 (-1.82%)
PETX : 4.44 (+0.45%)
ALKS : 45.02 (-0.22%)
Wired News - Alkermes Gets License Payment from Biogen Following Review of Preliminary Gastrointestinal Tolerability Data of BIIB098 for Multiple Sclerosis Treatment

LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want access to our free research report on Alkermes PLC (NASDAQ: ), all you need to do is sign up now by clicking the following link as the Company's latest...

ALKS : 45.02 (-0.22%)
Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday,...

ALKS : 45.02 (-0.22%)
Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

Alkermes plc (Nasdaq: ALKS) today announced it has received a $50 million payment from Biogen. This payment follows Biogen's review of preliminary gastrointestinal tolerability data from the ongoing clinical...

ALKS : 45.02 (-0.22%)
Detailed Research: Economic Perspectives on Bank of Nova Scotia, Eaton Corporation, Canadian National Railway, MakeMyTrip, Altisource Portfolio Solutions S.A., and Alkermes plc -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Bank of Nova Scotia (NYSE:BNS),...

BNS : 57.72 (+0.05%)
ASPS : 33.90 (+2.60%)
ALKS : 45.02 (-0.22%)
ETN : 78.37 (+0.71%)
CNI : 85.47 (+1.60%)
MMYT : 38.50 (+6.50%)
Key FDA Events in June Investors Need to Watch Out For

Investors in the healthcare industry are likely to keep a watch on upcoming PDUFA dates for key drugs in Jun 2018.

ARRY : 16.89 (-1.00%)
AKAO : 7.22 (+0.28%)
MRK : 62.94 (+0.66%)
GWPH : 148.88 (+1.72%)
ALKS : 45.02 (-0.22%)
VRX : 23.40 (-3.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade ALKS with:

Business Summary

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication...

See More

Key Turning Points

2nd Resistance Point 45.82
1st Resistance Point 45.42
Last Price 45.02
1st Support Level 44.54
2nd Support Level 44.05

See More

52-Week High 71.22
Fibonacci 61.8% 59.12
Fibonacci 50% 55.38
Fibonacci 38.2% 51.64
Last Price 45.02
52-Week Low 39.54

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar